

INTRODUCTION

- ✓ Mild cognitive impairment (MCI) is the transitional stage between normal cognitive aging and dementia.
- ✓ Descriptive studies of MCI have not been sufficiently conducted, and there is little information on patient characteristics and prognosis of MCI.
- ✓ MCI-to-Alzheimer's disease (AD) progression would be useful in considering future treatment strategies.
- ✓ This study aimed to characterize the progression of new MCI cases in Japan.

METHODS

Data

- ✓ The analysis was conducted using the Longevity Improvement & Fair Evidence Study (LIFE Study) database, which comprises municipality-level information centered on claims data.
- ✓ Claims data from April 2015 to March 2019 were obtained from 12 Japanese municipalities.
- ✓ We merged data from National Health Insurance enrollees aged <75 years and Long-term Care Insurance enrollees aged ≥75 years.

Case Patients

- ✓ New MCI cases were defined as those without any previous MCI diagnosis in the past 6 months.
- ✓ Subjects were identified as those with a recorded diagnosis of MCI (ICD-10: F067) and AD(G30).

Statistical Analysis

- ✓ Post-MCI progression was analyzed using (1) the incidence of MCI-to-AD progression among new MCI cases who could be followed-up for 36 months and (2) Kaplan-Meier curves to estimate MCI-to-AD progression among new MCI cases.


RESULTS

1. Patient characteristics upon new MCI diagnosis

	New MCI cases (n = 638)
Age, mean years [SD]	77.7 [7.5]
–64 years, n (%)	23 (3.6)
65–74 years, n (%)	154 (24.1)
75-84 years, n (%)	353 (55.3)
85-94 years, n (%)	104 (16.3)
95- years, n(%)	4 (0.6)
Female, n (%)	405 (63.5)
CCI, mean [SD]	1.42 (1.69)

SD; standard deviation, CCI; Charlson Comorbidity Index

2. Kaplan-Meier Curves of MCI-to-AD progression



CONCLUSION

- ✓ Characterizing the AD progression of MCI cases in Japan provides important fundamental data for future treatment strategies.
- ✓ Limitation: MCI and AD are both likely under-coded and/or under-diagnosed, so the generalizability of these results is unclear.

Funding

- ✓ The construction of the study database was funded by a KAKENHI Grant-in-Aid for Scientific Research (19H21590 & JP20H00563) from the JSPS.
- ✓ Data analysis and publication were funded by grants from Eisai Co., Ltd. And Biogen Inc.